Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)
Conditions
Interventions
Tazemetostat
Zanubrutinib
+2 more
Locations
1
United States
Huntsman Cancer Institute at University of Uta
Salt Lake City, Utah, United States
Start Date
September 12, 2025
Primary Completion Date
January 1, 2032
Completion Date
January 1, 2033
Last Updated
April 6, 2026
NCT06189391
NCT05008055
NCT05155839
NCT02134262
Lead Sponsor
University of Utah
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions